Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
The purpose of this study was to compare pen device-naïve patients' preferences for Humalog KwikPen (insulin lispro injection) (Eli Lilly and Company, Indianapolis, IN) to use of a vial and syringe and FlexPen(R) (insulin aspart injection) (Novo Nordisk A/S, Bagsvaerd, Denmark).



This open-label, randomized, crossover 1-day study tested the hypotheses that KwikPen was preferred to vial and syringe, and if this was found to be a significant preference, that KwikPen was preferred to FlexPen. Accuracy of doses prepared, ease of use via insulin device assessment battery, and preference via insulin device preference battery were administered following each pen evaluation, and a final preference question administered following the evaluation of both pens. Clinical measures were not included as subjects injected into an appliance to simulate the injection experience. Primary outcome variables were evaluated by Question 13 of the insulin device preference battery and the final preference question.



Among 232 enrolled patients randomized to 1 of 4 sequences (n = 58), Humalog KwikPen was significantly preferred over vial and syringe and over FlexPen. After patients were asked to assess Humalog KwikPen or FlexPen versus V&S by choosing "strongly agreed" or "agreed" to the following attributes: easy to use, easy to hold in their hands when injecting, and easy to press the injection button, the results exhibited significant differences in patient responses. Humalog KwikPen was significantly more accurate and was preferred to vial and syringe in appearance, quality, discretion, convenience, public use, easy to learn, easy to use, reliability, dose confidence, following insulin regimen, overall satisfaction, and recommendation to others.



Humalog KwikPen was significantly preferred over vial and syringe and FlexPen. When compared with vial and syringe, Humalog KwikPen and FlexPen were easier to use and operate, demonstrated superior accuracy of doses prepared, and preferred by pen-naïve users.
Ignaut
Debra A
DA
Insulin/Devices Medical, Eli Lilly and Company, Indianapolis, Indiana (Dr Ignaut, Ms Sarwat, Ms Murphy)
Schwartz
Sherwyn L
SL
The Diabetes/Glandular Disease Clinic, San Antonio, Texas (Ms Schwartz)
Sarwat
Samiha
S
Insulin/Devices Medical, Eli Lilly and Company, Indianapolis, Indiana (Dr Ignaut, Ms Sarwat, Ms Murphy)
Murphy
Heather L
HL
Insulin/Devices Medical, Eli Lilly and Company, Indianapolis, Indiana (Dr Ignaut, Ms Sarwat, Ms Murphy)
D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004209:Disposable Equipment; D016503:Drug Delivery Systems / Q000295:instrumentation*; D004867:Equipment Design / Q000295:instrumentation; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017060:Patient Satisfaction; D015203:Reproducibility of Results; D012646:Self Administration / Q000295:instrumentation*; D011795:Surveys and Questionnaires; D013594:Syringes
D007004:Hypoglycemic Agents; D007328:Insulin